Tech Company Financing Transactions
Nkarta Funding Round
Nkarta closed a $114 million Series B funding round on 9/6/2019. Investors included Samsara BioCapital, Amgen Ventures and Deerfield Capital.
Transaction Overview
Company Name
Announced On
9/6/2019
Transaction Type
Venture Equity
Amount
$114,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6000 Shoreline Ct. 102
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Nkarta (Nasdaq: NKTX) seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Hastings
Chief Financial Officer
Matthew Plunkett
Chief Medical Officer
Kanya Rajangam
Chief Scientific Officer
James Trager
VP - Bus. Development
Nadir Mahmood
VP - Manufacturing
Ralph Brandenberger
Browse more venture capital transactions:
Prev: 9/6/2019: RippleMatch venture capital transaction
Next: 9/6/2019: Saltbox venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs